Journal of Pain and Symptom Management
Volume 39, Issue 3 , Pages 477-485 , March 2010

Impact of Pain and Symptom Burden on the Health-Related Quality of Life of Hemodialysis Patients

  • Sara N. Davison, MD, MHSc (Bioethics), FRCP(C)

      Affiliations

    • Division of Nephrology & Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    • Corresponding Author InformationAddress correspondence to: Sara N. Davison, MD, 11-107 Clinical Sciences Building, Edmonton, Alberta, Canada T6G 2G3.
    • ,
  • Gian S. Jhangri, MSc

      Affiliations

    • Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada

,Accepted 12 August 2009.

References 

  1. Kimmel PL, Peterson RA, Weihs KL, et al. Aspects of quality of life in hemodialysis patients. J Am Soc Nephrol. 1995;6:1418–1426
  2. Fainsinger R, Davison SN, Brenneis C. A supportive care model for dialysis patients. Palliat Med. 2003;17:81–82
  3. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42:1239–1247
  4. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int. 2006;69:1621–1625
  5. Davison SN, Jhangri GS, Johnson JA. Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrol Dial Transplant. 2006;21:3189–3195
  6. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006;32(2):93–98
  7. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14:82–99
  8. Saini T, Murtagh FE, Dupont PJ, et al. Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med. 2006;20:631–636
  9. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage. 2006;31:58–69
  10. Davison SN, Jhangri GS. The impact of chronic pain on depression, sleep, and the desire to withdraw from dialysis in hemodialysis patients. J Pain Symptom Manage. 2005;30:465–473
  11. O'Donnell K, Chung JY. The diagnosis of major depression in end-stage renal disease. Psychother Psychosom. 1997;66:38–43
  12. Smith MD, Hong BA, Robson AM. Diagnosis of depression in patients with end-stage renal disease. Comparative analysis. Am J Med. 1985;79:160–166
  13. Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol. 2007;2:960–967
  14. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002;13:1307–1320
  15. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  16. DeOreo PB. The use of patient-based instruments to measure, manage, and improve quality of care in dialysis facilities. Adv Ren Replace Ther. 2001;8:125–130
  17. Ifudu O, Paul HR, Homel P, Friedman EA. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol. 1998;18:109–116
  18. McClellan WM, Anson CA, Birkeli K, Tuttle E. Functional status and quality of life: predictors of early mortality among patients entering treatment for end stage renal disease. J Clin Epidemiol. 1991;44:83–89
  19. Chang VT, Hwang SS, Kasimis B. Longitudinal documentation of cancer pain management outcomes: a pilot study at a VA medical center. J Pain Symptom Manage. 2002;24:494–505
  20. Vogl D, Rosenfeld B, Breitbart W, et al. Symptom prevalence, characteristics, and distress in AIDS outpatients. J Pain Symptom Manage. 1999;18:253–262
  21. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis. 2000;35:629–637
  22. Kimmel PL, Emont SL, Newmann JM, Danko H, Moss AH. ESRD patient quality of life: symptoms, spiritual beliefs, psychosocial factors, and ethnicity. Am J Kidney Dis. 2003;42:713–721
  23. Patel SS, Shah VS, Peterson RA, Kimmel PL. Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis. Am J Kidney Dis. 2002;40:1013–1022
  24. Weisbord SD, Fried LF, Arnold RM, et al. Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients. J Am Soc Nephrol. 2005;16:2487–2494
  25. Curtin RB, Bultman DC, Thomas-Hawkins C, Walters BA, Schatell D. Hemodialysis patients' symptom experiences: effects on physical and mental functioning. 562, 567–572, 574 Nephrol Nurs J. 2002;29:
  26. Hays RD, Kallich JD, Mapes DL, et al. Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.3: a manual for use and scoring. Qual Life Res. 1994;3:329–338
  27. Hays RD. RAND 36 health status inventory. New York: Harcourt Brace & Company; 1998;
  28. Ware JE, Kosinski M, Keller SD. A 12-time short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233
  29. Birbeck GL, Kim S, Hays RD, Vickrey BG. Quality of life measures in epilepsy: how well can they detect change over time?. Neurology. 2000;54:1822–1827
  30. Johnson JA, Maddigan SL. Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes. Qual Life Res. 2004;13:449–456
  31. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36 summary scales in a multiple sclerosis population. Med Care. 2000;38:1022–1028
  32. Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores?. Qual Life Res. 2001;10:395–404
  33. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med. 2000;108:609–613
  34. Weisbord SD, Carmody SS, Bruns FJ, et al. Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients. Nephrol Dial Transplant. 2003;18:1345–1352
  35. Weisbord SD, Kimmel PL. Health-related quality of life in the era of erythropoietin. Hemodial Int. 2008;12:6–15
  36. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573–578
  37. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  38. Levin NW, Lazarus JM, Nissenson AR. National Cooperative rHu Erythropoietin Study in patients with chronic renal failure—an interim report. The National Cooperative rHu Erythropoietin Study Group. Am J Kidney Dis. 1993;22(2 Suppl 1):3–12
  39. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996;7:763–773
  40. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000;11:335–342
  41. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361
  42. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  43. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials. 1991;12(Suppl 4):168S–179S
  44. Plantinga LC, Fink NE, Jaar BG, et al. Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis. Qual Life Res. 2007;16:755–765
  45. Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004;66:355–366
  46. U.S. Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: USRDS; 2007;
  47. Canadian Institute for Health Information. 2007 annual report—treatment of end-stage organ failure in Canada 1996 to 2005. Ottawa, Ontario, Canada: CIHI; 2008;
  48. Davison SN, Murtagh FEM, Higginson IJ. Methodological considerations for end-of life research in patients with chronic kidney disease. J Nephrol. 2008;21:268–282

 This study was partially funded by the Institute of Health Economics.

PII: S0885-3924(10)00089-8

doi: 10.1016/j.jpainsymman.2009.08.008

Journal of Pain and Symptom Management
Volume 39, Issue 3 , Pages 477-485 , March 2010

Article Tools